RT Journal Article SR Electronic T1 Clinical utility of 18F-FDG PET/CT in staging and treatment planning of urachal adenocarcinoma JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP jnumed.120.251561 DO 10.2967/jnumed.120.251561 A1 Jeeban P Das A1 Hebert Alberto Vargas A1 Soleen Ghafoor A1 Alvin C Goh A1 Gary A Ulaner YR 2020 UL http://jnm.snmjournals.org/content/early/2020/09/18/jnumed.120.251561.abstract AB Purpose: Our objective was to evaluate the impact of utility of 18Fluorine (18F)-Fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) in the management of urachal adenocarcinoma (UrC-ADC). Methods: A retrospective analysis of patients with UrC-ADC from 2001-2019 at Memorial Sloan Kettering was performed. Mayo stage prior to 18F-FDG-PET/CT, rates of detection of the primary malignancy and metastases on 18F-FDG PET/CT, Mayo stage after 18F-FDG-PET/CT, and changes in patient management were determined. Results: Of 21 patients with UrC-ADC prior to 18F-FDG-PET/CT, Mayo staging was I/II in 8, III in 3 and IV in 10. 18F-FDG-PET/CT detected previously unidentified metastases in 8 of 21 (38%) patients, resulting in upstaging of disease in 3 (14%) patients, and a change in treatment in 4 patients (19%). Conclusion: 18F-FDG PET/CT has clinical utility in patients with UrC-ADC by identifying metastatic disease not appreciated on anatomic imaging, leading to changes in staging and patient management.